Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Millennium, J&JPRD Begin Phase III Velcade Trial | Contract Pharma

What are you searching for?

Sign in

Millennium, J&JPRD Begin Phase III Velcade Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium Pharmaceuticals and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) initiated a Phase III trial of Velcade in combination with Rituxan in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin’s lymphoma (NHL). This study builds on clinical data observed in previous trials of Velcade that showed high objective response rates and a favorable safety profile across a variety of lymphomas.

The Phase III study is expected to enroll approximately 670 patients with relapsed or refractory, Rituxan naive or sensitive follicular NHL. Patients will be randomized to either the combination regimen of once-weekly Velcade plus Rituxan or Rituxan alone. The primary endpoint is progression-free survival. Secondary endpoints of the study include the overall response rate and duration of response as assessed by the International Workshop to Standardize Response Criteria for NHL (IWRC).

Previous trial results of Velcade in NHL showed overall response rates, including complete responses, of 54% in the weekly arm, and 51% in the twice-weekly arm with a similar total amount of drug received in both treatment arms. Additionally, data demonstrated response rates for single-agent Velcade as high as 56% in patients with relapsed or refractory follicular lymphoma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters